248 related articles for article (PubMed ID: 32732498)
1. Role of enterocyte-specific gene polymorphisms in response to adjuvant treatment for stage III colorectal cancer.
Suenaga M; Cao S; Zhang W; Matsusaka S; Okazaki S; Berger MD; Miyamoto Y; Schirripa M; Barzi A; Yamamoto N; Yamaguchi T; Lenz HJ
Pharmacogenet Genomics; 2021 Jan; 31(1):10-16. PubMed ID: 32732498
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer.
Suenaga M; Schirripa M; Cao S; Zhang W; Cremolini C; Lonardi S; Okazaki S; Berger MD; Miyamoto Y; Soni S; Barzi A; Yamaguchi T; Loupakis F; Falcone A; Lenz HJ
Pharmacogenomics J; 2021 Jun; 21(3):285-295. PubMed ID: 33542444
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
[TBL] [Abstract][Full Text] [Related]
4. p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
Oh HJ; Bae JM; Wen X; Jung S; Kim Y; Kim KJ; Cho NY; Kim JH; Han SW; Kim TY; Kang GH
Br J Cancer; 2019 Apr; 120(8):797-805. PubMed ID: 30894685
[TBL] [Abstract][Full Text] [Related]
5. Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial.
Song N; Pogue-Geile KL; Gavin PG; Yothers G; Kim SR; Johnson NL; Lipchik C; Allegra CJ; Petrelli NJ; O'Connell MJ; Wolmark N; Paik S
JAMA Oncol; 2016 Sep; 2(9):1162-9. PubMed ID: 27270348
[TBL] [Abstract][Full Text] [Related]
6. GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy.
Lin WR; Chiang JM; Liang KH; Lim SN; Lai MW; Tsou YK; Hsieh TY; Hsu CK; Yeh CT
Medicine (Baltimore); 2016 Apr; 95(17):e3487. PubMed ID: 27124048
[TBL] [Abstract][Full Text] [Related]
7. Feasibility of mFOLFOX6 as the adjuvant treatment after curative resection of metastases from colorectal cancer in Japanese patients.
Machida N; Yoshizaki K; Boku N; Yamazaki K; Onozawa Y; Fukutomi A; Yasui H; Taku K
Int J Clin Oncol; 2013 Apr; 18(2):279-84. PubMed ID: 22367535
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer.
Pectasides D; Karavasilis V; Papaxoinis G; Gourgioti G; Makatsoris T; Raptou G; Vrettou E; Sgouros J; Samantas E; Basdanis G; Papakostas P; Bafaloukos D; Kotoula V; Kalofonos HP; Scopa CD; Pentheroudakis G; Fountzilas G
BMC Cancer; 2015 May; 15():384. PubMed ID: 25956750
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of EGFR Expression for Patients With Stage III Colorectal Cancer Receiving Fluoropyrimidine Metronomic Maintenance Therapy After Radical Resection and Adjuvant Oxaliplatin-Based Chemotherapy.
Huang CW; Ma CJ; Su WC; Chen YT; Tsai HL; Yeh YS; Chang TK; Hsu WH; Yu FJ; Wang JY
Oncol Res; 2021 Sep; 28(7):701-714. PubMed ID: 32859280
[TBL] [Abstract][Full Text] [Related]
10. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.
Han Y; Cai H; Ma L; Ding Y; Tan X; Liu Y; Su T; Yu Y; Chang W; Zhang H; Fu C; Cao G
Eur J Cancer; 2013 Nov; 49(16):3420-30. PubMed ID: 23809767
[TBL] [Abstract][Full Text] [Related]
11. Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer.
Zhao J; Li W; Zhu D; Yu Q; Zhang Z; Sun M; Cai S; Zhang W
Med Oncol; 2014 Jan; 31(1):802. PubMed ID: 24338217
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05.
Boige V; Mendiboure J; Pignon JP; Loriot MA; Castaing M; Barrois M; Malka D; Trégouët DA; Bouché O; Le Corre D; Miran I; Mulot C; Ducreux M; Beaune P; Laurent-Puig P
J Clin Oncol; 2010 May; 28(15):2556-64. PubMed ID: 20385995
[TBL] [Abstract][Full Text] [Related]
13. KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer.
Deng Y; Wang L; Tan S; Kim GP; Dou R; Chen D; Cai Y; Fu X; Wang L; Zhu J; Wang J
Mol Oncol; 2015 Aug; 9(7):1341-7. PubMed ID: 25864038
[TBL] [Abstract][Full Text] [Related]
14. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.
Iveson TJ; Kerr RS; Saunders MP; Cassidy J; Hollander NH; Tabernero J; Haydon A; Glimelius B; Harkin A; Allan K; McQueen J; Scudder C; Boyd KA; Briggs A; Waterston A; Medley L; Wilson C; Ellis R; Essapen S; Dhadda AS; Harrison M; Falk S; Raouf S; Rees C; Olesen RK; Propper D; Bridgewater J; Azzabi A; Farrugia D; Webb A; Cunningham D; Hickish T; Weaver A; Gollins S; Wasan HS; Paul J
Lancet Oncol; 2018 Apr; 19(4):562-578. PubMed ID: 29611518
[TBL] [Abstract][Full Text] [Related]
15. Chronological Age and Risk of Chemotherapy Nonfeasibility: A Real-Life Cohort Study of 153 Stage II or III Colorectal Cancer Patients Given Adjuvant-modified FOLFOX6.
Laurent M; Des Guetz G; Bastuji-Garin S; Culine S; Caillet P; Aparicio T; Audureau E; Carvahlo-Verlinde M; Reinald N; Tournigand C; Landre T; LeThuaut A; Paillaud E; Canouï-Poitrine F
Am J Clin Oncol; 2018 Jan; 41(1):73-80. PubMed ID: 26669742
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
[TBL] [Abstract][Full Text] [Related]
17. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
[TBL] [Abstract][Full Text] [Related]
18. Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project.
Souglakos J; Boukovinas I; Kakolyris S; Xynogalos S; Ziras N; Athanasiadis A; Androulakis N; Christopoulou A; Vaslamatzis M; Ardavanis A; Emmanouilides C; Bompolaki I; Kourousis C; Makrantonakis P; Christofyllakis C; Athanasiadis E; Kentepozidis N; Karampeazis A; Katopodi U; Anagnosopoulos A; Papadopoulos G; Prinarakis E; Kalisperi A; Mavroudis D; Georgoulias V
Ann Oncol; 2019 Aug; 30(8):1304-1310. PubMed ID: 31228203
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX.
Ciardiello F; Normanno N; Martinelli E; Troiani T; Pisconti S; Cardone C; Nappi A; Bordonaro AR; Rachiglio M; Lambiase M; Latiano TP; Modoni G; Cordio S; Giuliani F; Biglietto M; Montesarchio V; Barone C; Tonini G; Cinieri S; Febbraro A; Rizzi D; De Vita F; Orditura M; Colucci G; Maiello E;
Ann Oncol; 2016 Jun; 27(6):1055-1061. PubMed ID: 27002107
[TBL] [Abstract][Full Text] [Related]
20. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
